News

Asterand has reported that its partner BTG plans to advance BGC20-1531, a novel EP4 receptor antagonist for the treatment of migraine headaches, to Phase IIa studies in the

Adcock Ingram will reportedly make the payment in cash, with an option for shareholders to re-invest up to 25% in the combined company. The Adcock Ingram offer equates

Champions Biotechnology, a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established a UK subsidiary,

Engage is expected to enroll 1,200 patients with abdominal aortic aneurysms at up to 80 medical centers across six continents. Patients who meet the single-arm study’s inclusion criteria

According to Wright Medical, the Prophecy program will enable surgeons to utilize basic CT or MRI scan technology to plan precise implant placement and alignment, before they enter

Tibotec, a division of Janssen-Ortho, has announced that Health Canada has approved Prezista for use in treatment-naive adults, dosed once daily in combination with other antiretroviral agents. The

Interest revenues amounted to $37,047 in the first quarter of 2009, compared with $259,434 in the first quarter of 2008. The change in interest revenue resulted from the

Mr Leach also resigned as a director of Integrated BioPharma, and his director and officer positions with its subsidiaries. Mr Leach will continue to be employed by the

Intercell, a biotechnology company, has initiated a Phase I clinical trial with the company’s vaccine candidate IC47 to prevent disease caused by the bacterium Streptococcus pneumoniae. This Phase